Future studies along this line of investigation might involve measuring the ability of CD73-positive EVs released from CRC tumors to produce adenosine and testing the efficacy of CD73 inhibitors against circulating EVs, as systemic immunosuppression might affect metastatic ability that could not be achieved by only tumoral CD73. The gene discussed is NT5E; the disease is colorectal carcinoma.